Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $42.33

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are covering the stock, Marketbeat reports. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $42.33.

Several equities research analysts recently commented on KROS shares. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Wedbush downgraded Keros Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $47.00 to $15.00 in a research note on Friday, January 17th. Piper Sandler cut their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, January 17th. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Oppenheimer cut their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. acquired a new stake in Keros Therapeutics during the 3rd quarter valued at $216,000. Intech Investment Management LLC acquired a new position in Keros Therapeutics during the third quarter valued at $603,000. Charles Schwab Investment Management Inc. lifted its stake in Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after acquiring an additional 32,492 shares in the last quarter. FMR LLC boosted its position in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after acquiring an additional 179,374 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Keros Therapeutics by 59.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock worth $312,000 after acquiring an additional 1,994 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $10.79 on Friday. The firm has a market capitalization of $437.66 million, a PE ratio of -2.07 and a beta of 1.39. Keros Therapeutics has a 1 year low of $9.78 and a 1 year high of $72.37. The stock has a fifty day moving average of $11.15 and a two-hundred day moving average of $34.30.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Equities research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.